EUVIMEDEUVIMED entdecken
Crossref

SMN2 as a therapeutic target in spinal muscular atrophy: advances in gene expression modulation

Michael Christian Ante Virata, Rizal Michael Ramos Abello, Edroico Mari Beltran Brillante, Michelle Baleña Corneta

Journal of Translational Genetics and Genomics · 24.09.2025 · 9 (4) · 268-85

DOI: 10.20517/jtgg.2025.56 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Translational Genetics and Genomics, online erschienen am 24.09.2025. Verfasst von Michael Christian Ante Virata und 3 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 102 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Spinal muscular atrophy (SMA) is a progressive neuromuscular degenerative disorder caused by mutations in the survival motor neuron 1 (SMN1) gene, leading to insufficient production of the survival motor neuron (SMN) protein. The nearly identical SMN2 gene modifies disease severity but generates only limited amounts of functional SMN protein due to a C-to-T transition in exon 7 that disrupts proper splicing. This review summarizes advances in understanding SMN2 splicing regulation and post-transcriptional modification in SMA pathogenesis. It discusses the roles of cis- and trans-acting elements in exon 7 inclusion, as well as the impact of epigenetic mechanisms such as histone acetylation and DNA methylation on SMN2 expression. This review also examines available therapeutic strategies, including antisense oligonucleotides (Nusinersen), small-molecule splicing modulators (Risdiplam and Branaplam), and gene therapy (Onasemnogene abeparvovec). Emerging approaches such as CRISPR/Cas9 genome editing and nanotechnology-based delivery systems are also highlighted. In addition, this review explores translational research using animal models, iPSC-derived neurons, and multi-omics approaches. Finally, it emphasizes the need for integrated therapeutic strategies that address both SMN-dependent and -independent pathways to improve treatment outcomes.

Zitieren

APA

Virata, M. C. A., Abello, R. M. R., Brillante, E. M. B., & Corneta, M. B. (2025). SMN2 as a therapeutic target in spinal muscular atrophy: advances in gene expression modulation. Journal of Translational Genetics and Genomics, 9(4), 268-85. https://doi.org/10.20517/jtgg.2025.56

Vancouver

Virata MCA, Abello RMR, Brillante EMB, Corneta MB. SMN2 as a therapeutic target in spinal muscular atrophy: advances in gene expression modulation. Journal of Translational Genetics and Genomics. 2025;9(4):268-85. doi:10.20517/jtgg.2025.56

BibTeX
@article{Virata2025,
  author = {Virata, Michael Christian Ante and Abello, Rizal Michael Ramos and Brillante, Edroico Mari Beltran and Corneta, Michelle Baleña},
  title = {SMN2 as a therapeutic target in spinal muscular atrophy: advances in gene expression modulation},
  journal = {Journal of Translational Genetics and Genomics},
  year = {2025},
  volume = {9},
  number = {4},
  pages = {268--85},
  doi = {10.20517/jtgg.2025.56}
}
Kostenlos starten →